141 related articles for article (PubMed ID: 10991968)
21. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
[TBL] [Abstract][Full Text] [Related]
22. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
Strain EC; Preston KL; Liebson IA; Bigelow GE
J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
[TBL] [Abstract][Full Text] [Related]
23. Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine, and saline.
Walker EA; Picker MJ; Granger A; Dykstra LA
J Pharmacol Exp Ther; 2004 Jul; 310(1):150-8. PubMed ID: 15044559
[TBL] [Abstract][Full Text] [Related]
24. Properties of pentazocine as a discriminative stimulus in the squirrel monkey.
White JM; Holtzman SG
J Pharmacol Exp Ther; 1982 Nov; 223(2):396-401. PubMed ID: 7131294
[TBL] [Abstract][Full Text] [Related]
25. Further characterization of the three-choice morphine, cyclazocine and saline discrimination paradigm: opioids with agonist and antagonist properties.
White JM; Holtzman SG
J Pharmacol Exp Ther; 1983 Jan; 224(1):95-9. PubMed ID: 6336785
[TBL] [Abstract][Full Text] [Related]
26. Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization.
White DA; Holtzman SG
J Pharmacol Exp Ther; 2005 Jul; 314(1):374-82. PubMed ID: 15843500
[TBL] [Abstract][Full Text] [Related]
27. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
28. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
Preston KL; Bigelow GE; Liebson IA
J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
[TBL] [Abstract][Full Text] [Related]
29. Dietary cadmium exposure alters characteristics of training, substitution, and tolerance when morphine is used as a discriminative stimulus.
Nation JR; Miller DK; Bratton GR
Neurotoxicology; 2000 Aug; 21(4):553-67. PubMed ID: 11022863
[TBL] [Abstract][Full Text] [Related]
30. Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle.
Prus AJ; Philibin SD; Pehrson AL; Porter JH
Behav Pharmacol; 2006 Mar; 17(2):185-94. PubMed ID: 16495726
[TBL] [Abstract][Full Text] [Related]
31. Relative efficacy of buprenorphine, nalbuphine and morphine in opioid-treated rhesus monkeys discriminating naltrexone.
Sell SL; McMahon LR; France CP
J Pharmacol Exp Ther; 2003 Sep; 306(3):1167-73. PubMed ID: 12766254
[TBL] [Abstract][Full Text] [Related]
32. Discriminative stimulus effects of intravenous heroin and its metabolites in rhesus monkeys: opioid and dopaminergic mechanisms.
Platt DM; Rowlett JK; Spealman RD
J Pharmacol Exp Ther; 2001 Nov; 299(2):760-7. PubMed ID: 11602692
[TBL] [Abstract][Full Text] [Related]
33. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Barrett AC; Smith ES; Picker MJ
J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
[TBL] [Abstract][Full Text] [Related]
34. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance.
Houtsmuller EJ; Walsh SL; Schuh KJ; Johnson RE; Stitzer ML; Bigelow GE
J Pharmacol Exp Ther; 1998 May; 285(2):387-96. PubMed ID: 9580575
[TBL] [Abstract][Full Text] [Related]
35. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers.
Walker DJ; Zacny JP
J Pharmacol Exp Ther; 1999 Jun; 289(3):1454-64. PubMed ID: 10336539
[TBL] [Abstract][Full Text] [Related]
36. Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects.
Schlaepfer TE; Strain EC; Greenberg BD; Preston KL; Lancaster E; Bigelow GE; Barta PE; Pearlson GD
Am J Psychiatry; 1998 Apr; 155(4):470-3. PubMed ID: 9545990
[TBL] [Abstract][Full Text] [Related]
37. Discriminative stimulus effects of buprenorphine in the rat.
Holtzman SG
Psychopharmacology (Berl); 1997 Apr; 130(3):292-9. PubMed ID: 9151365
[TBL] [Abstract][Full Text] [Related]
38. Cross-tolerance and mu agonist efficacy in pigeons treated with LAAM or buprenorphine.
Galici R; McMahon LR; France CP
Pharmacol Biochem Behav; 2005 Jul; 81(3):626-34. PubMed ID: 15946731
[TBL] [Abstract][Full Text] [Related]
39. Mu opioid mediated discriminative-stimulus effects of tramadol: an individual subjects analysis.
Strickland JC; Rush CR; Stoops WW
J Exp Anal Behav; 2015 Mar; 103(2):361-74. PubMed ID: 25664525
[TBL] [Abstract][Full Text] [Related]
40. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
